Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer

GenVec

Status and phase

Completed

Phase 2

Phase 1

Conditions

Head and Neck Neoplasms

Head and Neck Cancer

Treatments

Drug: TNFerade biologic

Study type

Interventional

Funder types

Industry

Identifiers

NCT00496236

GV-001.010

GV-001.010 (TNF-ELF)

Details and patient eligibility

About

This study is looking at the safety and tolerability of TNFeradeä Biologic combined with conventional once daily radiation therapy in elderly or frail patients with new onset locally advanced head and neck tumors.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 70 or older with an ECOG performance status 0-2,or
Patients > 18 years of age with ECOG performance status of 2 or greater, or
Patients > 18 years of age unsuitable for concurrent chemotherapy or surgery due to:
Renal failure, or
Severe cardiopulmonary disease, or
Other end-organ dysfunction that precludes the use of chemotherapy but does not preclude the administration of TNFerade™ Biologic or cetuximab
Tumor that is unresectable or inoperable and not amenable to regular concurrent chemoradiotherapy
Patients > 18 years of age with intermediate stage disease, stages II-III (T2-T3, N0-1MO) carcinoma of the head and neck, including oral cavity, pharynx larynx, paranasal sinuses and cervical esophagus. Selected patients with stage IV disease (T4N0-1M0) will also be considered for enrollment. Therapy is given with curative intent.
Disease should be clinically accessible (measurable or evaluable) to keep injection via direct intratumoral injection
Informed consent

Exclusion criteria

History of malignancy in the last 2 years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer, or localized early stage prostate cancer, with patients continually disease free, or cancers that are not felt to influence treatment for head and neck cancer and life expectancy of patient
Overt systemic metastatic disease
Previous radiation or chemotherapy for malignancy of the head and neck
Clinical evidence of active infection of any type
pregnant or lactating women
Experimental medications within the last 4 weeks prior to Day 1
Chronic treatment for greater than 6 months with steroids at doses above 10 mg/day prednisone (or equivalent)
Patients receiving hormone replacement therapy or hormonal contraceptives within 2 weeks of day 1
Patients who have undergone surgery within the last 1 month
Allergic reaction to cetuximab